Zhitong Finance App News, Lizhu Pharmaceutical (01513) issued an announcement. Recently, the company's subsidiary, Sichuan Guangda Pharmaceutical Co., Ltd. (Sichuan Everbright), received the “Drug Clinical Trial Approval Notice” (Notice No.: 2026LP03296) approved by the State Drug Administration, and agreed to carry out clinical trials of “vestibular migraine (ventricular migraine (ventricular migraine)”.

According to public information, this product is the first Class 1.1 innovative traditional Chinese medicine drug in China to enter registered clinical trials and directly targets vestibular migraine indications. It is a key variety in the company's innovative traditional Chinese medicine pipeline. The approval of this product to carry out clinical trials marks phased progress in the company's research and layout in the field of innovative traditional Chinese medicine, helping to further enrich the company's product pipeline and enhance the market competitiveness of the traditional Chinese medicine sector.

As of the disclosure date of this announcement, the total direct investment in R&D expenses of Tiange Dingmu Granule was approximately RMB 7.3358 million. This product was developed by the company in cooperation with Dongfang Hospital of Beijing University of Traditional Chinese Medicine, and the company enjoys all the rights of this product worldwide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.